New combo therapy aims to tackle Ultra-Resistant schizophrenia
NCT ID NCT05240976
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an anti-inflammatory drug to an NMDA-enhancing agent can improve thinking and memory in people with ultra-resistant schizophrenia. About 80 adults who have not responded well to clozapine will receive the combination or a placebo. The goal is to see if this approach can better control symptoms and boost cognitive function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Psychiatry, China Medical University Hospital
RECRUITINGTaichung, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?